TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06322758

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume customization in the acute respiratory distress syndrome
Description: During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal volume customization in the acute respiratory distress syndrome
Description: During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
Study: NCT04974788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Respiratory Muscle Training
Description: Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium Intensity Respiratory Muscle Training
Description: Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Respiratory Muscle Training
Description: Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
Study: NCT06057922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201 for Injection
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201 for Injection
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
Study: NCT05184426

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Ultrasound study to assess cardiac anatomy and function

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Ultrasound study to assess cardiac anatomy and function

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance
Description: MR to assess cardiac anatomy, function and tissue damage

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance
Description: MR to assess cardiac anatomy, function and tissue damage

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: Cathteterization to assess coronary anatomy. Intravascular ultrasound to obtained a detailed assessment of vessels anatomy. Guidewire pressure to assess microcirculation

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: Cathteterization to assess coronary anatomy. Intravascular ultrasound to obtained a detailed assessment of vessels anatomy. Guidewire pressure to assess microcirculation

Intervention type: DIAGNOSTIC_TEST
Intervention: Endomyocardial biopsy
Description: Optic microscopy, immunofluorescence, transmission electron microscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Endomyocardial biopsy
Description: Optic microscopy, immunofluorescence, transmission electron microscopy
Study: NCT05665062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNCAR-001
Description: SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNCAR-001
Description: SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-009
Description: STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-009
Description: STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: lymphodepletion
Study: NCT05239832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Fusion Protein Vaccine
Description: The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Study: NCT06560515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Dinoprostone
Description: induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Dinoprostone
Description: induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol
Study: NCT06561399

Intervention type: COMBINATION_PRODUCT
Intervention: TACE, Lenvatinib combination with Sintilimab sequential radiotherapy
Description: TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Sintilimab (200mg administered intravenous injection on Day 1 of each 21-day cycle) for 2 months. Sequential radiotherapy method and dosage are comprehensively evaluated by radiologists, hepatobiliary surgeons, and oncologists, and discussed by a multidisciplinary team
Study: NCT04992611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension (Early)
Description: Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping rise time the same as the sleep restriction period, but extending sleep by going to bed earlier. This produces a sleep extension that is aligned for Morning Larks and misaligned for Night Owls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension (Early)
Description: Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping rise time the same as the sleep restriction period, but extending sleep by going to bed earlier. This produces a sleep extension that is aligned for Morning Larks and misaligned for Night Owls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension (Late)
Description: Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping bedtime the same as the sleep restriction period, but extending sleep by rising later. This produces a sleep extension that is misaligned for Morning Larks and aligned for Night Owls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension (Late)
Description: Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping bedtime the same as the sleep restriction period, but extending sleep by rising later. This produces a sleep extension that is misaligned for Morning Larks and aligned for Night Owls.
Study: NCT05707507

Intervention type: OTHER
Group type: OTHER
Intervention: Place of treatment
Description: Patients with an infectious diseases have to be treated with a specify antimicrobial therapy. The differences between the arms is about the possibility to continue with the treatment in or out of the hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Place of treatment
Description: Patients with an infectious diseases have to be treated with a specify antimicrobial therapy. The differences between the arms is about the possibility to continue with the treatment in or out of the hospital.
Study: NCT05651126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 5 mg
Description: Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 5 mg
Description: Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 5 mg
Description: Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 2 mg
Description: Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
Study: NCT04943224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: \< 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: \< 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,
Study: NCT04999852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe and Sound Protocol
Description: SSP is a non-invasive acoustic vagus nerve stimulator consisting of 5 hours of filtered and processed music designed to promote efficient regulation of autonomic state, and available through an app. The SSP is delivered via a mobile app and may fall under the heading of medical devices under the category of software functions/mobile medical applications.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
Study: NCT06092229

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasonography with TACA approach
Description: identification of the cricothyroid membrane, using ULTRASONOGRAPHY with TACA approach , a procedure used to prepare for front of neck airway access
Study: NCT05557825

Intervention type: RADIATION
Intervention: Photobiomodulation Therapy
Description: Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
Study: NCT05651126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 2 mg
Description: Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 2 mg
Description: Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive placebo
Study: NCT04261894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMIZE
Description: The study intervention is implementation of the OPTIMIZE perinatal care checklist with patient navigation support. The checklist will contain perinatal care components to be assessed for each participant. Specifically, the checklist will be built into the electronic health record as a secure digital record of: (1) the participant's adherence to the recommended prenatal and postpartum visit schedule, (2) the completion of procedures and processes in a participant's prenatal and postpartum standard care plan, and (3) the completion of processes to address social determinants of health, along with completion of referrals to appropriate support resources. The OPTIMIZE checklist will also include records of patient navigation review, engagement, and tracking of barrier status and resolution
Study: NCT05167981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RETAINWORKS
Description: The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
Study: NCT06036498

Intervention type: DEVICE
Intervention: Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography
Description: We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.

Intervention type: DEVICE
Intervention: Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography
Description: We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.

Intervention type: DEVICE
Intervention: Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography
Description: We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.

Intervention type: DEVICE
Intervention: Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography
Description: We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.

Intervention type: DEVICE
Intervention: Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography
Description: We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.

Intervention type: DEVICE
Intervention: Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography
Description: We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.

Intervention type: DEVICE
Intervention: Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography
Description: We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.
Study: NCT05883943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook® Venous Valve System
Description: The Cook® Venous Valve is a permanent prosthetic, bicuspid, one-way flow valve designed to be percutaneously implanted into the peripheral deep venous system. The Cook® Venous Valve Delivery System is used to percutaneously deliver the Cook® Venous Valve into the deep venous system.
Study: NCT06459271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Managing Cancer And Living Meaningfully (CALM)
Description: Our team has developed a brief, manualized, individual and couple-based psychotherapeutic intervention for patients living with advanced cancer and their primary caregivers called Managing Cancer and Living Meaningfully (CALM). CALM is a brief supportive-expressive therapy consisting of 3-6 sessions of 30-60 minutes delivered over the course of 3-6 months. This tailored therapy is focused on the most common challenges and concerns facing individuals living with advanced cancer. These four broad content domains are: 1) symptom management and communication with healthcare providers; 2) changes in self and in relationships with close others; 3) sense of meaning and purpose in life; and 4) hopes and fears about the future and mortality. The aim is to offer patients and caregivers reflective space and a supportive environment to reflect on and process the various practical and profound aspects of their life while facing advanced illness.
Study: NCT06025188

Intervention type: OTHER
Intervention: training set
Description: LASSO regression analysis, Logistic regression analysis, Nomogram

Intervention type: OTHER
Intervention: training set
Description: LASSO regression analysis, Logistic regression analysis, Nomogram
Study: NCT06250491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep active rTMS with Hesed coil
Description: This brain neurostimulation method targets the motor cortex bilaterally

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Deep active rTMS with Hesed coil
Description: This brain neurostimulation method targets the motor cortex bilaterally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS with Hesed coil
Description: This brain sham neurostimulation method targets the motor cortex bilaterally

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS with Hesed coil
Description: This brain sham neurostimulation method targets the motor cortex bilaterally
Study: NCT05627739

Intervention type: DRUG
Intervention: Mycophenolate Mofetil
Description: Glucocorticoid is started at a dose of 0.5-0.8 mg/kg/day, and 60 mg daily was the highest dose. Mycophenolate mofetilwas is started at a dose of 0.5-1.0g bid.
Study: NCT05439148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection
Description: Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
Study: NCT04684901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AlloWrap® Amniotic Membrane
Description: AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair.
Study: NCT05048004

Intervention type: PROCEDURE
Intervention: QMODE intervention
Description: Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For standard ablation, a Thermocool Smarttouch SF (Biosense Webster) catheter will be used (50 W, target ablation index of 550).

Intervention type: PROCEDURE
Intervention: QMODE+ intervention
Description: Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For comparison, catheter ablation performed using very high power with a maximum of up tp 90 W (QMODE +) will be used.
Study: NCT05730166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Conditioning stimulus
Description: Mechanical stimulus on the upper trapezius of the non-dominant side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Conditioning stimulus
Description: Mechanical stimulus on the upper trapezius of the non-dominant side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Conditioning stimulus
Description: Mechanical stimulus on the upper trapezius of the non-dominant side.
Study: NCT05810818

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling treatment will be consisting of two treatments per week

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self Stretching
Description: Self stretching groups both will receive a TrP manual interventions and stretching protocol
Study: NCT06105034

Intervention type: PROCEDURE
Intervention: interventional techniques, the severity of placental invasion, and various placental positions and suture techniques
Description: Clinically, severe complications of PA include severe obstetric hemorrhage leading to disseminated intravascular coagulopathy (DIC), iatrogenic injury to the ureters, bladder, bowel, respiratory distress syndrome (RDS), acute transfusion reactions, electrolyte imbalance, and renal failure. In women with PA, the expected blood loss at delivery is 3000- 5000 mL, About 90% of patients require a blood transfusion with 40% requiring more than ten units of packed cell transfusion

Intervention type: PROCEDURE
Intervention: interventional techniques, the severity of placental invasion, and various placental positions and suture techniques
Description: Clinically, severe complications of PA include severe obstetric hemorrhage leading to disseminated intravascular coagulopathy (DIC), iatrogenic injury to the ureters, bladder, bowel, respiratory distress syndrome (RDS), acute transfusion reactions, electrolyte imbalance, and renal failure. In women with PA, the expected blood loss at delivery is 3000- 5000 mL, About 90% of patients require a blood transfusion with 40% requiring more than ten units of packed cell transfusion
Study: NCT04811183

Intervention type: BEHAVIORAL
Intervention: Pharmaceutical consultation
Description: Selection of patients for a pharmaceutical consultation with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week after consultation. Elements on knowledge and adherence of treatment will be collected.